Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma

Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-01, Vol.15 (1), p.e33538
Main Authors: Azad, Farhan, Moyer, Ross, Miranda, Clive J, Gravina, Matthew
Format: Article
Language:English
Subjects:
Blood tests
Carbon dioxide
Cardiology
Case reports
Chemotherapy
Creatinine
Ejection fraction
Emergency medical care
Heart failure
Hemoglobin
Inhibitor drugs
Laboratories
Medical prognosis
Metabolism
Multiple myeloma
Oncology
Patients
Potassium
Targeted cancer therapy
Tomography
Ultrasonic imaging
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following the use of PIs in MM, a malignancy not known to cause TLS, has seldom been reported. We present a case of a patient with a known diagnosis of MM who received prior therapy including bortezomib, a first-generation PI, developing worsening heart failure and new onset TLS days after the administration of carfilzomib.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.33538